Diurnal Receives Patent Grant from European Patent Office

Specialty pharmaceutical company, Diurnal Group, has announced the receipt of a patent for its hydrocortisone granules in capsules for opening, Alkindi, from the European Patent Office. The company revealed the news in a Nov. 20, 2020 press release.

Patent EP2780003 for the medical use of Alkindi in the treatment of pediatric patients with adrenal insufficiency, will protect Diurnal’s product in the European market until 2032. Equivalent patents have already been granted in the United Kingdom, Japan, Australia, Israel, South Africa, South Korea, and the United States (for Alkindi Sprinkle).

“With the rapid commercialization of Alkindi being a core focus for Diurnal, we are pleased to receive this patent grant by the European Patent Office,” said Martin Whitaker, CEO of Diurnal, in the press release. “This patent, which builds on our strong global intellectual property position for the product, provides protection in Europe until 2032, supporting our continued commitment to provide Alkindi to pediatric patients suffering from adrenal insufficiency.”

Source: Diurnal